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Abstract 
The modern medical literature implicates malaria, and particularly the potentially fatal form of cerebral malaria, with 
a risk of neurocognitive impairment. Yet historically, even milder forms of malaria were associated in the literature 
with a broad range of psychiatric effects, including disorders of personality, mood, memory, attention, thought, 
and behaviour. In this article, the history of psychiatric effects attributed to malaria and post-malaria syndromes is 
reviewed, and insights from the historical practice of malariotherapy in contributing to understanding of these effects 
are considered. This review concludes with a discussion of the potentially confounding role of the adverse effects of 
anti-malarial drugs, particularly of the quinoline class, in the unique attribution of certain psychiatric effects to malaria, 
and of the need for a critical reevaluation of the literature in light of emerging evidence of the chronic nature of these 
adverse drug effects.
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Background
This review, written for the psychiatrist as much as for 
the malariologist, serves as an introduction to what 
by modern perspectives may be viewed as surprising 
areas of common interest. The disciplines of psychiatry 
and malariology were united briefly in the early to mid 
twentieth century in the historical practice of malari-
otherapy, in which patients were intentionally inoculated 
with malaria for its presumed therapeutic neuropsychi-
atric effects. Although this practice has long fallen out 
of favour and although the two disciplines have subse-
quently diverged, insights from malariotherapy and more 
broadly the field of malariology have continued to make 
important contributions to psychiatry in the modern era.
Untreated or delayed treatment of malignant Plasmo-
dium falciparum malaria infection may result in coma. 
This cerebral complication of malaria is implicated par-
ticularly with lasting cognitive deficits that owing to the 
high prevalence of disease worldwide may contribute sig-
nificantly to the global burden of psychiatric morbidity 
[1]. Yet similarly, anti-malarial drugs, particularly of the 
quinine-like class of quinolines commonly used in treat-
ment and prevention of disease, are also increasingly rec-
ognized to exert potentially chronic psychiatric adverse 
effects that may also contribute to this global burden of 
morbidity [2].
This review, inspired by an earlier seminal work [3], 
synthesizes over a century of critical literature from psy-
chiatry and malariology—ranging from anecdotal histori-
cal observations to evidence from modern randomized 
controlled trials—to explore the evolving understanding 
of the psychiatric effects of malaria and of anti-malarial 
drugs. In this review, the evolution of psychiatric effects 
attributed to malaria is described, from the historical per-
spective in which a broad range of symptoms were attrib-
uted to the disease, to the current understanding of the 
more limited psychiatric effects of cerebral malaria (CM) 
and post-malaria syndromes. Next, malariotherapy and 
its historical role in psychiatry are described. Lastly, the 
psychiatric effects of anti-malarial drugs, particularly of 
the quinoline class, are reviewed, including a discussion 
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regarding the potential confounding effect that these 
may have had on symptoms historically associated with 
malaria.
Psychiatric effects of malaria
Although early descriptions of the psychiatric effects of 
malaria first appeared in the ancient medical literature of 
Hippocrates and Galen [4, 5], it was only many centuries 
later that descriptions of these effects became relatively 
common. Such descriptions grew particularly detailed 
in the aftermath of World War I (WWI), where malaria, 
epidemic on the Macedonian front between 1916 and 
1918, was unexpectedly found to be the leading cause of 
psychiatric disorders among soldiers of the Allied powers 
fighting there [6].
Detailed reports in the literature from this era 
described a seemingly bewildering set of psychiatric 
effects attributed to both severe and mild forms of the 
disease. Early reports had described dreamlike states 
[7], anterograde amnesia, difficulties with concentration, 
disorientation, and forgetfulness [8], confusional psycho-
sis, dementia, “melancholia”, and mania [9] emerging in 
patients recovering from severe malaria. During this era, 
mild chronic or intermittent malaria infection had also 
become associated with symptoms of “neurasthenia”, 
including depression, irritability, anxiety, and insomnia 
[10]. In subsequent years, even more severe symptoms 
such as confusion [11], intermittent psychoses, and delir-
ium were also commonly attributed to those with mild 
forms of malaria [12].
This literature even warned of the potential for missed 
diagnoses of malaria prior to the onset of malarial fever 
among psychiatric patients admitted for care and thought 
to be suffering from delirium and psychoses [13]. Many 
such patients were diagnosed with malaria only some 
time later at the onset of fever, or when their symptoms 
progressed to coma. These reports described a common 
prodrome of hallucinations, anxiety, crying, violence, agi-
tation, and a dreamy and confusional state [13].
So common and diverse became the psychiatric effects 
attributed to both severe and mild forms of malaria 
during the post-WWI era, that an entire textbook, well 
received by psychiatrists at the time [14], was published 
with chapters featuring case reports of malarial psy-
choses, “dementia praecox”, confusional and delusional 
insanity, mania, “melancholia”, delirium, and dementia 
attributable to the disease. As noted by the author in his 
preface, “very few known syndromes are absent from the 
list apparently arising from malarial infection” [15].
By World War II (WWII), growing US and allied mili-
tary experience, particularly in the South Pacific, had 
identified similar psychiatric effects associated with 
malaria. Reports from US military clinicians noted a 
characteristically confusional form of psychosis, as well 
as persecutory, grandiose, bizarre delusions, and symp-
toms of anxiety, depression, and mania associated with 
both severe and mild forms of the disease [16, 17]. Yet 
others had begun to challenge the true association of 
many of these symptoms with malaria, noting “too great 
a tendency to blame malaria for many of these symp-
toms” [16], with the temporal association of certain of 
these symptoms suggesting to other authors a toxic pro-
cess [16].
Despite such growing suspicions, the psychiatric effects 
of malaria were still considered “more common than 
are generally known” [4], and a military journal edito-
rial noted that malaria should be considered “associated 
with protean mental states” [18]. Psychiatric symptoms 
also remained clearly associated in the literature of the 
era with even the mild chronic and relapsing forms of 
disease, with a case report describing psychosis develop-
ing weeks prior to the onset of fevers from the generally 
benign Plasmodium vivax malaria [17].
Reports from among soldiers of the Vietnam War era 
similarly described mostly transient cases of psychosis, 
and impaired memory and concentration generally fol-
lowing admission for treatment for malaria [19], often 
lagging admission by some days, and typically without 
evidence of such symptoms while previously febrile [20]. 
Neuropsychological testing of certain of these patients 
both soon after their acute illness and following their 
recovery identified common patterns of deficits, par-
ticularly in tests of recent memory, visual organization, 
psychomotor speed, and visual motor integration [21, 
22]. Decades later, follow-up of malaria patients from the 
Vietnam War demonstrated lasting changes in personal-
ity, depression, and symptoms of partial seizure [23], as 
well as deficits on tests of memory, and other evidence 
of chronic cognitive dysfunction on neuropsychological 
testing [24].
In more recent studies of broadly defined malaria infec-
tions, acute malaria among children [25], and multiple 
recurrent malaria infections have been associated with 
adverse effects on short-term cognitive performance 
[26]. Similarly, in recent reviews, among chronic psychi-
atric effects, the most common and strongest evidence 
exists for a risk of chronic cognitive impairment follow-
ing successful malaria treatment [27–30]. Additional 
retrospective studies have attributed a risk of subclinical 
depressive and anxiety symptoms [31], as well as altered 
executive functioning [32], particularly following severe 
malaria infection.
Cerebral malaria
Unlike past usage of the term, which had been sig-
nificantly broader in scope [33], and had included 
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presentations that had involved organic mental syndrome 
and even acute personality change [21], the modern strict 
definition of CM has gradually evolved to require altera-
tions in consciousness for diagnosis [34, 35]. This mod-
ern definition of CM, which was developed for research 
purposes [36], and which is considered a diagnosis of 
exclusion [37], specifically limits use of the term to a 
patient with coma occurring in the presence of malignant 
P. falciparum malaria parasitaemia [38]. The strong and 
highly sensitive and specific association of such clinically-
defined CM with objective signs, including malaria retin-
opathy, has significantly improved diagnostic reliability 
[39, 40], particularly among children in tropical countries 
who are primarily affected by the disorder.
Unlike historical definitions, the modern definition of 
CM is primarily described as an acute neurological dis-
order and is notably less associated in the literature with 
acute psychiatric symptoms [33, 41]. Some authors have 
questioned its acute association with psychosis [42], 
although early case reports [43] and reviews [44] through 
the 1990s continued to describe self-limiting acute psy-
chosis occurring following treatment for CM.
Prospective follow-up of patients specifically with CM 
are limited, but small studies of children find increased 
risk of cognitive deficit [45] lasting through 2  years of 
follow-up [46]. In children surviving CM confirmed by 
retinopathy, certain measures of retinopathy were associ-
ated with chronic deficits in attention and cognitive abil-
ity [40]. A prospective study of children with a spectrum 
of severe malaria including CM also found sub-acute 
behavioural problems and decreased attention [47].
Retrospective studies of children with CM also report 
long-term impairments in cognition and executive 
functioning [48] as well as developmental and cognitive 
impairments including in speech, language, and memory 
[49–51], with seizure during acute infection emerging as 
a strong risk factor [52]. Small retrospective studies in 
adults have also shown chronic impairments in verbal 
learning and abstract reasoning [53].
With the rise in diagnostic specificity of malaria disor-
ders, investigators have been able to distinguish chronic 
sequelae of treated CM from those of other compli-
cations of malaria, including severe malarial anaemia 
(SMA) without coma. Consistent with the findings in 
other anemic disorders, children under 5  years of age 
with SMA have also been found to suffer long-term cog-
nitive impairment [54].
Post‑malaria syndromes
With the evolution of the definition of CM requiring 
neurological signs during acute P. falciparum parasitae-
mia for diagnosis, three additional disorders have been 
defined to describe cases in which neuropsychiatric 
sequelae become manifest primarily following treatment 
and resolution of acute malaria infection, independent 
of the severity of prior disease, including occasionally 
occurring following illness from benign P. vivax infec-
tion. One disorder has been referred to as delayed cer-
ebellar ataxia (DCA) [55], or in some cases as related 
delayed cerebellar syndromes [56, 57]. A later somewhat 
distinct disorder has been referred to as post-malaria 
neurological syndrome (PMNS) [58] while a related dis-
order of acute disseminated encephalomyelitis (ADEM) 
has been defined which is diagnosed with the aid of 
neuroimaging studies. Although disagreement has been 
raised as to whether certain of these constitute unique 
disorders [59], they appear to differ from each other 
and from the modern disorder of CM in regards to the 
latency, frequency, and type of reported psychiatric 
findings.
Although psychiatric symptoms are only rarely associ-
ated with delayed cerebellar syndromes in the literature, 
when reported, these have included giddiness [56], alter-
ations in attention [60], and word-finding difficulties [61].
Similarly, in cases of ADEM, although neurologi-
cal findings tend to predominate, psychiatric symptoms 
including alterations in sensorium [62], confusion [63], 
disorientation [64], and language difficulties have been 
reported [65].
In contrast to ADEM and the delayed cerebellar syn-
dromes, psychiatric symptoms have been far more com-
monly reported with PMNS, to include the broader 
range of symptoms historically associated with malaria 
infections, including anxiety [66], temporospatial diso-
rientation [67], difficulties with word-finding [68], acute 
confusion [69], mood changes, [70], psychosis with hal-
lucinations, persecutory delusions, and mania [58], and 
disturbances in behaviour [71].
Malariotherapy of psychiatric disease
Ancient knowledge of the psychiatric effects of malaria 
included accounts describing reductions in aggressive-
ness among the mentally ill after bouts of malaria [72]. 
In the early twentieth century, growing awareness of the 
reported psychiatric effects of malaria, and recognition 
that febrile illness had proven therapeutic in the treat-
ment of neurosyphillis [73]—a debilitating and epidemic 
condition then known as “general paresis” for which no 
effective treatments were then available [74]—prompted 
the first formal experimentation with the practice of 
malariotherapy.
According to the first published description of the 
practice [75], for which its author would subsequently 
win the Nobel Prize in medicine [76–78], neurosyphillis 
patients were intentionally inoculated with blood-stage 
benign forms of malaria, allowing upwards of ten cycles, 
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or paroxysms, of intermittent fever prior to treatment of 
the infection with available anti-malarial drugs [75].
Early case reports of this technique described common 
and pronounced improvements in psychiatric symptoms 
including reduced irritability, aggression, mania, psy-
chosis, confusion, amnesia, and disorientation following 
such fever treatment [75, 79–84]. Complete cures, later 
categorized as remissions by some authors [85, 86], were 
initially reported in up to a third of patients. Partial cures 
were reported in about a half [87], although subsequent 
reports claimed somewhat greater risks and more mixed 
success rates [86, 88–93]. Intriguingly, following the ter-
mination of fever paroxysms by treatment with available 
anti-malarial drugs, a distinct mental state described 
as “paraphrenic” or late psychosis was occasionally 
described with transient confusional, delusional, incoher-
ent, hallucinatory, and manic-depressive features [94].
So common became the practice of malariotherapy 
soon after its introduction that concerns of autochtho-
nous spread of malaria led to health ministries establish-
ing standard guidelines for the practice [95], including 
the enforcement of vector controls in the vicinity of 
patients [96, 97]. Although mosquito inoculation, rather 
than blood-stage inoculation, had been recognized 
as associated with a risk of malaria relapse [98], and to 
thus pose an increased risk of autochthonous spread, the 
growing popularity of malariotherapy for the treatment 
of non-syphilitic psychiatric patients [99], together with 
concerns regarding cross-contamination with Treponema 
pallidum, led to increasing use of direct mosquito inocu-
lation for the purpose [85, 100, 101].
Subsequent experience would demonstrate that the 
results of treatment of other psychiatric disorders 
(including chronic “dementia praecox” or schizophrenia, 
as well as manic-depressive psychosis) were mixed and 
perceived as less successful [73, 94] and with the devel-
opment of effective antibiotics for treatment of neuro-
syphillis, the practice of malariotherapy gradually fell into 
disuse.
Psychiatric effects of anti‑malarial drugs
Although many classes of drug have wide clinical appli-
cations as anti-malarials and also are known to cause 
psychiatric effects, the quinoline derivatives are unique 
in medical history for having been used ubiquitously to 
treat and prevent malaria, often to the exclusion of other 
classes of drug. For example, with few alternatives, prior 
to WWI, malaria was invariably treated and prevented 
with quinine, or occasionally with one of the other natu-
rally occurring quinoline-based cinchona alkaloids [102, 
103]. Similarly, in the aftermath of WWI and through 
WWII, the only other anti-malarials that came into 
reliable use were synthetic quinolines initially developed 
by German scientists [102].
It was only in the decades following WWII, with the 
gradual development and deployment of drugs of alter-
native classes, to include proguanil and pyrimethamine 
[102], the discovery of the anti-malarial activity of tet-
racyclines [104, 105], and recently, the isolation of nat-
urally-occurring qinghaosu [106], or artemisinin, from 
Artemisia annua [107, 108], that effective and widely 
used alternatives to the quinolines emerged both for pre-
vention and treatment of disease.
While the quinolines have remained in common use 
through the present day, unlike these newer anti-malar-
ial classes, the utility of certain members of the quino-
line class in treating and preventing malaria has become 
progressively compromised through rising awareness 
of symptoms of idiosyncratic intoxication and central 
nervous system (CNS) toxicity associated with their 
use. Suggestive of a broad class effect spanning common 
structural variations, anti-malarial quinolines with psy-
chiatric effects that are commonly described in the litera-
ture include the naturally occurring 4-quinolinemethanol 
cinchona alkaloids quinine and quinidine, whose use as 
anti-malarials predominated prior to WWII; the syn-
thetic acridine derivative quinacrine (which may be con-
sidered a ring-substituted 4-aminoquinoline), whose use 
reached a peak during that war; the synthetic 4-amino-
quinolines including chloroquine, whose use expanded 
widely following WWII; the synthetic 4-quinolinemetha-
nol mefloquine, developed in the aftermath of the Viet-
nam War and whose use took the place of chloroquine 
throughout the 1980s and 1990s, and the synthetic 
8-aminoquinolines, which have been used sporadically 
since their first development following WWI, but which 
are now being considered for expanded use in global 
malaria control efforts.
Quinine and the cinchona alkaloids
The earliest human experience with the quinolines dates 
to discovery of the naturally-occurring drug quinine, 
a 4-quinolinemethanol alkaloid first isolated from the 
bark of the Cinchona tree in the seventeenth century, 
together with the related cinchona alkaloid quinidine 
[109]. Although reports from the early twentieth cen-
tury noted that quinine could have significant psychiatric 
effects [11], including causing depression, mania, irrita-
bility and personality change [110], and that these might 
not be distinguished from those attributed to disease [7], 
only relatively recently has it become clear that quinine, 
independent of malaria infection, may cause a serious 
toxic state marked by symptoms including delirium and 
confusion [111, 112].
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In contrast, a broader range of psychiatric effects spe-
cifically due to quinidine have been widely reported in 
the literature, including mood change [113], auditory hal-
lucinations [114, 115], visual hallucinations and delusions 
[115, 116], paranoia [116, 117], confusion, and delirium 
[116, 118].
Quinacrine
Quinacrine, a derivative of acridine dye first synthesized 
in the early 1930s [119], marketed initially under the 
names erion and atabrine [120], then later also under the 
name Mepacrine [121], may be considered a ring substi-
tuted 4-aminoquinoline. In early reports of its use, it was 
noted to induce “definite cases of delirium and mental 
disturbances” [122], including symptoms of depression 
[123], and delusional insanity. Case reports described 
acute personality and behavioural change, severe insom-
nia and anxiety described as an “impression of impending 
death” [124], visual hallucinations, and cognitive dys-
function. One patient complained that “a large part of his 
brain was out of action” [124], while another patient was 
described as manic, restless, disoriented, and suffering 
visual hallucinations that “snakes and fantastic animals 
were crawling on the floor” [125].
Although early marketing materials for the drug 
acknowledged “mental disturbances which have been 
observed in a few instances during treatment” [126], it 
was also emphasized that disorders of the nervous sys-
tem, including sudden delirium and delusional insan-
ity, were “not infrequent in the course of acute malarial 
fevers” [126], and that it was “important to distinguish 
between those due to malaria itself and those which may 
be attributable to the drug” [126].
With shortages of quinine during WWII, quinacrine 
was added to the US pharmacopoeia in 1942 [127], and 
was quickly prioritized for military use both as treatment 
and as a suppressive prophylaxis throughout the war 
[128]. Although studies of the acute toxicity of quinacrine 
had been planned during a wartime anti-malarial drug 
development effort [129], these were soon deprioritized 
after they were declared to be of “minor importance” to 
military leadership [130]. Although early studies in the 
UK had suggested that quinacrine caused “troublesome 
dreams” [131], and independent studies in the US had 
noted slight increases in nervousness [132], it was ini-
tially unclear whether such presumed toxic effects were 
actually due to quinacrine or merely to a contaminant 
[128, 133].
Towards the end of the war, however, sufficient expe-
rience had accumulated, including from rechallenge 
experiments, for wartime researchers to conclude that 
quinacrine use was definitely associated with a toxic psy-
chosis distinct from the effects of malaria, often of abrupt 
onset [134, 135], described as including “mania, catato-
nia, and paranoid and hallucinatory states” [136], and 
typically developing only several days after the start of 
treatment [134]. Authors noted the psychosis was typi-
cally marked either by “excitement, hallucinations, and 
delusions” with an affect of “euphoria and expansiveness” 
[137], or alternatively with “retardation, disorientation, 
and amnesia to recent events, together with confabu-
lation” [137], where affect was predominantly “one of 
bewilderment and fearfulness” [137].
In controlled tests of intellectual functioning, a large 
proportion of subjects administered quinacrine were 
found to suffer significant subclinical impairment, and in 
two cases of psychosis that developed subsequently, tests 
of intellectual functioning had showed mild impairment 
prior to onset [138]. The authors concluded that “among 
a large group” administered quinacrine, “some would 
show clinical confusion” [139]. A separate controlled 
study conducted among healthy US military physicians 
clearly demonstrated quinacrine induced changes in the 
electroencephalograph [140], accompanied by apprehen-
sion, restlessness, insomnia, “awakening dreams which at 
times were of frightening and nightmare quality” [141], 
and symptoms of mania described as “an unusual push of 
activity” associated with “tension, irritability, and anxi-
ety” [142]. One subject experiencing panic attack and 
flight of ideas noted he “felt so bombarded by stimuli 
that he could not deal with them effectively” [141]. The 
patient became very anxious, depressed, confused, and 
was thought to be suffering delirium, although his con-
sciousness was in fact preserved [141, 142].
With the publication of such research findings ini-
tially restricted due to wartime considerations, official 
documents acknowledged only that “psychological dis-
turbances occasionally appear” with use of quinacrine 
[143], and that the drug could cause “mild excitement” 
and rarely, “acute maniacal psychoses” [144]. Despite the 
imprecision of official reports, quinacrine was nonethe-
less recognized by numerous wartime physicians as a 
potential cause of psychiatric disorders [145], and as the 
war ended and in subsequent years as restrictions were 
rescinded, numerous publications appeared describing 
psychiatric effects associated with the drug’s use.
One ecological study linked an increase in a combat 
unit’s rate of psychoses to their initiation of quinacrine 
for prophylaxis [146]. A case report described a previ-
ously healthy soldier suffering three distinct episodes 
of mania, each occurring with recurrent use of quina-
crine both for prophylaxis and treatment [147]. Another 
detailed case report described a patient initially free of 
psychiatric history and thought to be suffering from cer-
ebral malaria, who following 5  days of treatment with 
quinacrine developed excitement, talkativeness, and 
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rambling, progressing to depression, impaired concen-
tration, disorientation in time and place, anterograde 
and retrograde amnesia, and delusions. These symptoms 
lasted 2 weeks [148]. One case series of those treated with 
quinacrine reported psychoses developing 0–10  days 
after the last day of malarial fever [149]; another between 
3–12  days following the start of quinacrine [137]; while 
another reported an even wider latency of onset of 
2–22  days, with a similarly wide range in time to satis-
factory recovery of 1–30 days. Of significance, in at least 
four cases in the series, failure to recover and the devel-
opment of chronic psychiatric disorders was noted [135].
In the immediate postwar years, a few additional stud-
ies and case reports of psychiatric effects from quinacrine 
were also published [150], including a series describ-
ing inappropriate sexual behaviour associated with psy-
choses [151]. In a final published study of 31 previously 
healthy Army Medical Department officers who volun-
teered to take the drug experimentally at treatment doses 
[152], 77  % suffered some form of mental disturbances: 
71  % complained of abnormal, anxious and disturbing 
and rarely terrifying dreams; 58 % developed sleep distur-
bances, with loss of up to half of normal sleep, prompting 
sedative use to treat insomnia in two-fifths of these, or 
26 % of the total; 39 % went on to develop severe psychic 
disturbances, of which a quarter, of 10 % of the total, suf-
fered frank psychoses with delusions, hallucinations, and 
profound changes in mood, including mania; 35 % com-
plained of tension; 32 % complained of restlessness, and 
29 % depression. During an earlier phase of the trial when 
the drug had been administered at lower prophylactic 
dose rates, 29 % had noted mild complaints, most signifi-
cantly abnormal dreams and sleep disturbances, which 
were deemed “the most reliable warning sign” of the 
development of “more severe reactions” [152]. Intrigu-
ingly, it was reported that during earlier widespread use 
of the drug, such “minor toxic symptoms of restlessness, 
insomnia, and increased dreaming might frequently have 
passed unnoticed as a manifestation of malaria” [152].
Chloroquine and other 4‑aminoquinolines
Chloroquine, a 4-aminoquinoline, was also first synthe-
sized in the 1930s by German scientists, who named it 
resochin [153, 154]. Expecting a quinacrine-like effect 
in initial clinical testing, presumably owing to the drugs’ 
structural similarities, its toxicity was described as being 
“so great in comparison to its effect” [155], that the drug 
was deemed “too toxic for practical use in humans” [153] 
and further German development was abandoned. The 
drug was rediscovered only during the subsequent US 
WWII drug development effort [154], where it was ini-
tially referred to as SN-7618. Chloroquine was investi-
gated during this WWII era effort only after the potential 
utility of a related 4-aminoquinoline, sontochin, later 
referred to as SN-6911, was noted following the Allied 
invasion of Tunisia, where it was found that the drug 
was undergoing clinical testing by Axis-affiliated French 
researchers [153].
In the WWII era of US testing, sontochin was noted 
to induce acute confusional psychosis and nervousness 
at high doses [156], and in postwar testing, was found to 
induce a wider variety of psychiatric symptoms, includ-
ing anxiety, nervousness, a sensation of “being on edge”, 
irascibility, and irritability at lower prophylactic dose 
rates [157]. In contrast, during similar testing, chloro-
quine appeared to have only “minor toxic manifestations” 
[158], and in published WWII era trials, appeared devoid 
of psychiatric effects. Considered more effective and less 
toxic than sontochin during the WWII development 
effort [153], chloroquine was also considered “better” 
than quinacrine, and “much better” than quinine [159], 
and by the early 1950s it had begun to replace both drugs 
for the treatment and prophylaxis of malaria [160–162].
With increasing use however, chloroquine came to be 
associated with similar idiosyncratic cases of toxicity as 
those noted previously with the cinchona alkaloids and 
with quinacrine and sontochin. These took the form of 
various psychiatric symptoms including sleep distur-
bances and insomnia [163–165], mood and personality 
change [165, 166], impulsivity, flight of ideas, and inap-
propriate behaviour [165, 167], persecutorial and para-
noid delusions [165, 168], delusional misidentification 
[169, 170], depersonalization [166], visual and auditory 
hallucinations [165, 171], and mania [172, 173]. Suicidal-
ity [167] and completed suicide [174–176] were also not 
uncommonly reported. Although psychiatric symptoms 
from chloroquine have been noted to often resemble a 
brief psychotic or delusional disorder [177–179], on care-
ful evaluation they are more likely to feature visual hal-
lucinations, derealization, restlessness, agitation, and 
anxiety than other cases of psychosis [180].
A case of severe psychosis with features of deperson-
alization and anxiety that developed under controlled 
research settings following chloroquine therapy for 
induced malaria was causally attributed by the research-
ers to the drug and not to malaria disease; following reso-
lution of psychosis the patient experienced difficulties 
with concentration that lasted 4  months [181]. A sepa-
rate case of transient amnesia linked to the drug, [182], 
and difficulties with concentration [183], confusion 
[184], delirium, and catatonia [165, 185] have also been 
reported.
Mefloquine
Mefloquine is a synthetic 4-quinolinemethanol analogue 
of quinine that was developed by the US military amid 
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concerns of rising chloroquine resistance during the 
Vietnam War [186] through a subsequent drug develop-
ment effort similar to that of the earlier WWII era [187] 
that spanned the 1960s–1980s [188]. Although once 
commonly considered the drug of choice for treatment 
and prophylaxis of malaria and marketed under the trade 
name Lariam, use of mefloquine has been severely lim-
ited by awareness of significant idiosyncratic CNS toxic-
ity [189] which, as with quinacrine [152], has been found 
to affect a sizeable minority of users at prophylactic dos-
ages and a majority of users at treatment dosages [189]. 
According to recent European product labelling [190], 
very commonly reported psychiatric effects occurring in 
>10 % of prophylactic users of mefloquine include abnor-
mal dreams and insomnia, while commonly reported 
psychiatric effects occurring in 1–10  % of prophylactic 
users include anxiety and depression.
As with earlier generations of quinoline anti-malarials, 
and consistent with product label warnings of encepha-
lopathy, case reports of psychiatric effects from meflo-
quine typically describe a complex and diverse range of 
effects on mood, personality, thought, cognition, sleep, 
and behaviour [191]. These include asthenia [192], mel-
ancholia [193], anxiety [194], phobias [195, 196], feel-
ings of unrest [197, 198], paranoia [199], increased 
self-esteem [200, 201], impaired judgment [198], social 
disinhibition [192, 202], giddiness [203], altered sexual 
libido [204], manic behaviour and paranoid delusions 
or psychosis [194, 200, 202, 204], hyperreligiosity [204], 
depersonalization [192, 198, 205], concentration and cog-
nitive problems [197], problems with word finding [201], 
disorientation [193, 198, 206], symptoms of amnesia and 
confusion or disorientation [192, 193, 203], sleep disor-
ders [207, 208], severe nightmares, [209] sleep paralysis 
and “flashbacks” [201], suicidal ideation [210], and sui-
cide [176, 211–213].
On initial presentation, individuals suffering from these 
diverse effects may appear to be suffering from a poten-
tially wide range of psychiatric disorders that span the 
diagnostic nosology, to include anxiety, depressive, bipo-
lar, psychotic, dissociative, personality, conversion, and 
factitious disorders [189, 191, 198]. In particular, the psy-
chiatric effects of mefloquine have been noted to poten-
tially confound the diagnosis of a number of psychiatric 
disorders prevalent in military settings, including post-
traumatic stress disorder [189, 214].
Severe and life-threatening psychiatric symptoms from 
mefloquine, including suicidal ideation and suicide, may 
be preceded by often subtle prodromal symptoms includ-
ing even mild disturbances in sleep and dreaming [215]. 
Although such symptoms have often previously been 
attributed to other causes and their critical significance 
overlooked even by influential authorities [216–218], 
both the European and US product labelling now explic-
itly direct the discontinuation of the drug at the onset 
of any psychiatric symptom [190]. Even the earliest 
approved US mefloquine product insert appeared to echo 
the conclusions of prospective studies of quinacrine con-
ducted decades earlier [152] listing “anxiety, depression, 
restlessness or confusion” as potentially prodromal to a 
“more serious event” and requiring the drug’s discontinu-
ation [190].
Similarly, while psychiatric symptoms from meflo-
quine were previously considered reversible and self-lim-
iting, the US product label for mefloquine was recently 
updated to include a boxed warning (or “black box”) that 
psychiatric effects from mefloquine could last years after 
use [219]. A recent follow-up study has found a size-
able proportion of those previously reporting adverse 
events from the drug complain of long-term psychiatric 
symptoms including cognitive dysfunction years after 
use [220]. Mefloquine has been convincingly linked to 
an increased risk of PMNS [58, 221], and a number of 
reviews have observed that certain psychiatric symptoms 
observed following malaria might plausibly be due to this 
and related quinoline anti-malarials [36, 44].
8‑Aminoquinolines
The 8-aminoquinolines were among the first synthetic 
quinoline anti-malarials. Pamaquine (also known as plas-
mochin), developed by German scientists [222, 223], and 
in use since the 1920s [224] was initially thought to be 
free of CNS toxicity, but a fatal case of fatal human tox-
icity, marked by symptoms of apprehension and restless-
ness, revealed evidence of extensive brain and brainstem 
neurotoxicity [225]. By the late 1940s, other synthetic 
8-aminoquinoline anti-malarials in common use prior 
to WWII, or introduced during the WWII drug devel-
opment effort, had been linked to a severe neurotoxic 
syndrome [226–228], potentially masking more subtle 
psychiatric effects, such as previously reported mild psy-
chosis [229, 230].
Primaquine, the only synthetic 8-aminoquinoline to 
safely emerge from the post-WWII era drug develop-
ment program, although long considered safe and only 
rarely associated with psychiatric adverse effects [231], 
has been linked to rare reports of confusion, amnesia, 
and depression [232, 233]. Similarly, symptoms reported 
with the experimental 8-aminoquinoline tafenoquine, 
originally developed by the US military and now in late-
stage development [234] and anticipated for use both as 
a replacement for mefloquine and primaquine [235, 236] 
and in mass drug administration campaigns for global 
malaria control [234] have been described in randomized 
trials as similar to those of chloroquine [237]. In a recent 
blinded trial, tafenoquine was found to cause a slightly 
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higher incidence of psychiatric symptoms than meflo-
quine, including abnormal dreams, agitation, anxiety, 
amnesia, and paranoia [238], with other reported symp-
toms including insomnia and depression [239].
Other anti‑malarials
In contrast to the quinoline class of anti-malarials, there 
is a paucity of data on the psychiatric effects of newer 
anti-malarial classes, including the tetracyclines, and 
artemisinins. What evidence does exists suggests these 
drugs cause a narrower range, and typically fewer and 
less extreme psychiatric symptoms than do the anti-
malarial quinolines.
For example, in contrast to trials of tetracycline in 
combination with mefloquine [240], early trials of tetra-
cycline monotherapy for treatment of malaria reported 
no psychiatric adverse effects [104]. Early trials of mino-
cycline monotherapy for treatment and prophylaxis also 
reported no psychiatric adverse effects [241]. Indeed, 
reviews of the use of tetracyclines [242] and specifically 
doxycycline [243] in malaria do not specifically mention 
adverse psychiatric effects, and one recent review sug-
gested these are “nearly nonexistent” [244]. Despite this, 
a number of studies comparing doxycycline to meflo-
quine report psychiatric symptoms such as insomnia and 
nightmares occurring, albeit less commonly than with 
mefloquine [245, 246]. Additionally, a recent case series 
has directed attention to the potential for rare anxiety 
and suicidality from doxycycline [247].
In contrast, pyrimethamine, typically used in combi-
nation with sulfadoxine, appears to have few psychiat-
ric effects. Recent reviews do not specifically mention 
adverse psychiatric effects from the drug [248, 249], 
although early observational studies suggested the com-
bination presented a risk of insomnia and depression, 
although less commonly than from quinoline anti-malar-
ials [250]. A recent trial of sulfadoxine-pyrimethamine 
against mefloquine also noted sleep disturbance occur-
ring with use of the drug, although similarly less com-
monly than with mefloquine [251].
Likewise, the drug combination atovaquone-proguanil, 
commonly marketed under the trade name Malarone®, 
also appears to have few psychiatric effects. As with the 
other drugs mentioned in this section, recent reviews 
also do not specifically mention adverse psychiatric 
effects from the drug [252]. Although one review sug-
gested that atovaquone-proguanil is “the best tolerated 
of all antimalarial medications”, psychiatric symptoms, 
particularly sleep disturbance and abnormal dreams, do 
occur with use of the drug, although again less commonly 
than with quinoline anti-malarials including mefloquine 
[253] and chloroquine-proguanil [254]. Additionally, 
and unlike as is the case with mefloquine [190] and with 
quinacrine before it [152], such psychiatric symptoms 
from atovaquone-proguanil are not considered pro-
dromal or predictive of more serious neuropsychiatric 
adverse effects, and do not mandate discontinuation of 
the drug at their onset.
Lastly, and particularly given suggestive evidence of 
CNS toxicity from the artemisinins [255–259], psychi-
atric effects from anti-malarials of this class, including 
the semi-synthetic derivatives artemether, artesunate, 
and dihydroartemisinin, should be considered plausible 
in spite of a paucity of observational and experimental 
evidence of this effect. The ascertainment of psychiatric 
effects from the artemisinins is made particularly chal-
lenging both by their widespread use in the treatment of 
symptomatic malaria [260, 261], and by their ubiquitous 
combination with other anti-malarial drugs, including 
the quinoline drugs amodiaquine and piperaquine [262], 
which are themselves not well studied for psychiatric 
effects. Although a recent systematic review found con-
sistently higher rates of psychiatric effects, particularly 
sleep disturbances, with artemisinin-based combination 
therapies containing mefloquine than with those contain-
ing other drugs, these cited studies were not designed to 
assess the unique effects of artemisinins [260], and no 
prospective studies have assessed the psychiatric effects 
of artemisinin monotherapy alone.
Conclusions
This review has demonstrated that malaria, regardless 
of its severity, has historically been associated in the lit-
erature with certain common psychiatric effects that 
resemble those now known to be caused by certain anti-
malarial drugs. This review has also demonstrated that 
as awareness of the adverse psychiatric effects of anti-
malarial drugs has grown in the modern era, the number 
of psychiatric effects commonly attributed in the litera-
ture to malaria, and particularly to less severe forms of 
the disease, has steadily decreased.
Earlier historical eras, when the psychiatric effects of 
malaria were considered far broader than they are today, 
coincided with a period of ubiquitous exposure to quino-
lines, both as prophylaxis and in subsequent treatment of 
disease. Similarly, more modern eras, in which the psy-
chiatric effects of malaria have been generally considered 
to be more limited, have coincided with a period of more 
widespread use of alternative classes of anti-malarial 
drugs less commonly associated with psychiatric effects. 
This ecological trend suggests the distinct possibility that 
some psychiatric effects previously attributed to malaria 
may have been due in whole or in part to the effects of 
quinoline anti-malarials.
While malaria, and particularly in its modern definition 
of CM, is undoubtedly associated with a risk of cognitive 
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impairment, the insights presented in this article should 
draw attention to the potentially significant confounding 
effects of anti-malarial exposure in the causal attribution of 
certain other psychiatric symptoms unique to malaria. This 
suggests a need to critically reevaluate the existing evidence 
base for the potential effects of such confounding.
The insights presented here should also underscore the 
importance both of designing future studies of the psy-
chiatric effects of malaria to control for such confound-
ing as much as is feasible, and also of more thoroughly 
assessing and characterizing those effects potentially 
attributable to anti-malarials, including those drugs cur-
rently under development and testing, and planned for 
use in global malaria control efforts, informed by knowl-
edge of their common adverse psychiatric effects.
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